SRR934783
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 45.630749014454665
- age_years
- 26
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.502
- G2M_CHECKPOINT+0.496
- E2F_TARGETS+0.458
- PROTEIN_SECRETION+0.422
- MYC_TARGETS_V1+0.413
- NOTCH_SIGNALING+0.411
- MITOTIC_SPINDLE+0.408
- MTORC1_SIGNALING+0.304
- UV_RESPONSE_DN+0.247
- UNFOLDED_PROTEIN_RESPONSE+0.210
Top 10 suppressed
- KRAS_SIGNALING_DN-0.431
- PANCREAS_BETA_CELLS-0.390
- COAGULATION-0.222
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.219
- APICAL_SURFACE-0.214
- HYPOXIA-0.213
- SPERMATOGENESIS-0.198
- ESTROGEN_RESPONSE_LATE-0.184
- UV_RESPONSE_UP-0.177
- ESTROGEN_RESPONSE_EARLY-0.146
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.900 |
| 2 | SRR934870 | — | — | 0.879 |
| 3 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.865 |
| 4 | SRR934914 | — | — | 0.858 |
| 5 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.856 |
| 6 | 8E898165-F557-4D73-9D67-ED735BE256B2 | — | — | 0.854 |
| 7 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.853 |
| 8 | SRR934724 | — | — | 0.853 |
| 9 | SRR934795 | — | — | 0.852 |
| 10 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.502 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.496 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.458 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.422 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.413 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.411 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.408 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.304 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.247 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.204 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.153 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.145 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.136 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.125 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.122 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.106 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.106 | Idelalisib | — uncovered |